Abstract
The results ofin vivo biokinetic investigation of the photodynamic activity of a series of new photosensitizers, including a tetraazachlorine derivative (2,3,3a,21а-tetrahydro-2-methyl-3а,8,13,18-tetraphenyl-5,10,15,20-tetraaza-1Н,22Н,24Н-pyrrolo[3, 4-b]porphine), two difluoroboryl-substituted complexes of diphenylazadiisoindolylmethene (N,N-difluoroboryl-N-[3-(4-tert-butylphenyl)-2Н-isoindol-1-yl)]-N-[3-(4-tert-butylphenyl)-1Н-isoindol-1-yliden]amine and N,N-difluoroboryl-1-[3-(4-methoxyphenyl)-2Н-isoindol-1-yl)]-N-[3-(4-methoxyphenyl)-1Н-isoindol-1-yliden]amine), and sulfanyl-substituted phthalocyanine (1,8,15,22-tetrakis(tert-butylsulfanyl)-29Н,31Н-phthalocyanine) are reported. Upon intravenous injection in the form of micellar suspensions in 4% aqueous solutions of Cremophor EL and Proksanol 268, the compounds under consideration exhibit pronounced photodynamic activity in mice bearing solid form of Ehrlich tumor and sarcoma S-37. A comparison of the tumor growth rate and the time to attaining a critical tumor volume in the test and control groups shows evidence for a high photodynamic activity of the new photosensitizers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
